TCM
ADVM

Teza Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Teza Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,106
Closed -$148K – 501
2016
Q4 		$148K Buy
+5,106
New +$167K 0.21% 189

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Teza Capital Management's ADVM Position: Q1 2017 in Review

Teza Capital Management sold out of Adverum Biotechnologies (ADVM) in Q1 2017, closing a stake of 5,106 shares — an estimated $148K sold.

Teza Capital Management first reported a position in ADVM in Q4 2016 and held it in 1 quarter. The position peaked at $148K in Q4 2016. 75 funds tracked by Wall St. Rank hold ADVM as of Q1 2017.

  • Teza Capital Management reported no remaining Adverum Biotechnologies position as of Q1 2017 after selling out during the quarter.
  • Teza Capital Management sold 5,106 Adverum Biotechnologies shares in Q1 2017, an estimated $148K.
  • Teza Capital Management first reported a position in Adverum Biotechnologies in Q4 2016 and held it in 1 quarter.
  • Teza Capital Management's Adverum Biotechnologies position peaked at $148K in Q4 2016.
  • 75 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2017.

Based on Teza Capital Management's 13F filing for Q1 2017, filed 4 May 2017.